JP2017537960A - 肝疾患および胃腸疾患の治療に使用するためのｆｘｒアゴニストとしてのアザビシクロオクタン誘導体 - Google Patents

肝疾患および胃腸疾患の治療に使用するためのｆｘｒアゴニストとしてのアザビシクロオクタン誘導体 Download PDF

Info

Publication number
JP2017537960A
JP2017537960A JP2017532168A JP2017532168A JP2017537960A JP 2017537960 A JP2017537960 A JP 2017537960A JP 2017532168 A JP2017532168 A JP 2017532168A JP 2017532168 A JP2017532168 A JP 2017532168A JP 2017537960 A JP2017537960 A JP 2017537960A
Authority
JP
Japan
Prior art keywords
compound
formula
methoxy
cyclopropyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017532168A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537960A5 (https=
Inventor
バドマン，マイケル
ビー． クリックスタイン，ロイド
ビー． クリックスタイン，ロイド
ラフィテ，ブライアン
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54979887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2017537960(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2017537960A publication Critical patent/JP2017537960A/ja
Publication of JP2017537960A5 publication Critical patent/JP2017537960A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
JP2017532168A 2014-12-18 2015-12-08 肝疾患および胃腸疾患の治療に使用するためのｆｘｒアゴニストとしてのアザビシクロオクタン誘導体 Pending JP2017537960A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462093586P 2014-12-18 2014-12-18
US62/093,586 2014-12-18
PCT/IB2015/059450 WO2016097933A1 (en) 2014-12-18 2015-12-08 Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases

Publications (2)

Publication Number Publication Date
JP2017537960A true JP2017537960A (ja) 2017-12-21
JP2017537960A5 JP2017537960A5 (https=) 2019-01-24

Family

ID=54979887

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017532168A Pending JP2017537960A (ja) 2014-12-18 2015-12-08 肝疾患および胃腸疾患の治療に使用するためのｆｘｒアゴニストとしてのアザビシクロオクタン誘導体

Country Status (17)

Country Link
US (2) US20170368038A1 (https=)
EP (1) EP3233083A1 (https=)
JP (1) JP2017537960A (https=)
KR (1) KR20170095965A (https=)
CN (1) CN107106555A (https=)
AU (1) AU2015365481B2 (https=)
BR (1) BR112017011972A2 (https=)
CA (1) CA2970866A1 (https=)
CL (1) CL2017001566A1 (https=)
IL (1) IL252596A0 (https=)
MX (1) MX2017008057A (https=)
PH (1) PH12017501046A1 (https=)
RU (1) RU2017125365A (https=)
SG (1) SG11201704340VA (https=)
TN (1) TN2017000243A1 (https=)
TW (1) TW201628615A (https=)
WO (1) WO2016097933A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020500211A (ja) * 2016-11-04 2020-01-09 へパジーン セラピューティクス インコーポレイテッド Ｆｘｒモジュレーターとしての窒素含有複素環式化合物
JP2021501220A (ja) * 2017-11-01 2021-01-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ファルネソイドｘ受容体モジュレーターとしての架橋二環化合物
JP2022518603A (ja) * 2019-01-31 2022-03-15 中国医▲薬▼研究▲開▼▲発▼中心有限公司 芳香環又は芳香族複素環化合物、その製造方法及び医薬使用
JP2023539385A (ja) * 2020-06-30 2023-09-13 オクヴィルク，ゼレン グアニル酸シクラーゼｃ（ｇｕｃｙ２ｃ）アゴニストおよび短鎖脂肪酸またはそのプロドラッグの組み合わせを含む医薬組成物

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
WO2016161003A1 (en) 2015-03-31 2016-10-06 Enanta Phamraceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2017189651A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017201152A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017201150A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
WO2017201155A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds
MX385718B (es) 2016-06-13 2025-03-18 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4).
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
CN116854681A (zh) 2016-08-23 2023-10-10 阿德利克斯股份有限公司 用于治疗代谢病状和病症的激素受体调节剂
WO2018039384A1 (en) 2016-08-23 2018-03-01 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators
PE20190972A1 (es) * 2016-09-14 2019-07-09 Novartis Ag Combinacion de agonistas de fxr
US10450306B2 (en) 2016-10-04 2019-10-22 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
RU2019113150A (ru) * 2016-10-05 2020-11-06 Новартис Аг Комбинация композиций, содержащих агонисты fxr, предназначенная для лечения или предупреждения фиброзирующего, цирротического заболевания или нарушения
WO2018081285A1 (en) 2016-10-26 2018-05-03 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
PT3600309T (pt) 2017-03-28 2022-10-03 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças hepáticas
PL3612520T3 (pl) 2017-04-12 2022-03-21 Il Dong Pharmaceutical Co., Ltd. Pochodne izoksazolu jako agoniści receptora jądrowego i ich zastosowania
KR102400183B1 (ko) * 2017-07-06 2022-05-18 수안주 바이오파마슈티컬 컴퍼니 리미티드 Fxr 작용제
EP3681881B1 (en) * 2017-09-14 2022-11-02 Ardelyx, Inc. Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders
CN111511731B (zh) 2017-11-01 2023-05-23 百时美施贵宝公司 作为法尼醇x受体调节剂的烯烃化合物
CN111278817B (zh) 2017-11-01 2023-05-16 百时美施贵宝公司 作为法尼醇x受体调节剂的多环化合物
AU2018360575A1 (en) 2017-11-01 2020-06-18 Bristol-Myers Squibb Company Alkene spirocyclic compounds as farnesoid X receptor modulators
KR102731924B1 (ko) 2017-11-01 2024-11-19 브리스톨-마이어스 스큅 컴퍼니 파르네소이드 x 수용체 조정제로서의 스피로시클릭 화합물
WO2019118571A1 (en) 2017-12-12 2019-06-20 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
KR20200102415A (ko) 2017-12-22 2020-08-31 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 이소옥사졸 유도체, 그 제조 방법 및 그 용도
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
US10829486B2 (en) 2018-02-14 2020-11-10 Enanta Pharmacueticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
CN110357875B (zh) * 2018-04-10 2022-06-21 浙江海正药业股份有限公司 氮杂双环辛烷类衍生物、其制备方法及其在医药上的用途
CN110357876B (zh) * 2018-04-10 2022-06-28 浙江海正药业股份有限公司 氮杂双环辛烷类衍生物及其制备方法和用途
WO2020001304A1 (zh) * 2018-06-26 2020-01-02 轩竹（海南）医药科技有限公司 Fxr受体激动剂
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
EP3911647B1 (en) 2019-01-15 2023-12-13 Gilead Sciences, Inc. Isoxazole compound as fxr agonist and pharmaceutical compositions comprising same
AU2020221371A1 (en) 2019-02-15 2021-10-07 Bristol-Myers Squibb Company Substituted amide compounds useful as farnesoid x receptor modulators
JP7465883B2 (ja) 2019-02-15 2024-04-11 ブリストル－マイヤーズ スクイブ カンパニー ファルネソイドｘ受容体モジュレータとしての置換二環式化合物
CN113727973B (zh) 2019-02-15 2025-08-29 百时美施贵宝公司 可用作类法尼醇x受体调节剂的取代酰胺化合物
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
CA3233305A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
CN111825701B (zh) * 2019-04-19 2023-12-08 正大天晴药业集团股份有限公司 含苯并噻唑的三环类fxr调节剂化合物
WO2020231917A1 (en) 2019-05-13 2020-11-19 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
KR20220035365A (ko) 2019-07-18 2022-03-22 엔요 파마 인터페론의 부작용을 감소시키는 방법
WO2021104022A1 (zh) * 2019-11-29 2021-06-03 广东东阳光药业有限公司 Tropifexor的新晶型及其制备方法
CN114728955A (zh) * 2019-11-29 2022-07-08 广东东阳光药业有限公司 Tropifexor的新晶型及其制备方法
IL293892A (en) 2020-01-15 2022-08-01 Inserm Institut National De La Sant? Et De La Rech M?Dicale Use of fxr agonists for treating an infection by hepatitis d virus
WO2021252392A1 (en) * 2020-06-09 2021-12-16 Viking Therapeutics, Inc. Compositions and methods for the treatment of liver disorders
JP2024502673A (ja) 2021-01-14 2024-01-22 ウエヌイグレックオ・ファーマ Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果
CN113292555B (zh) * 2021-04-28 2022-03-18 武汉纽瑞斯医药科技有限公司 一种Tropifexor的制备方法
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強
CN116987062A (zh) * 2023-08-03 2023-11-03 中国热带农业科学院分析测试中心 一种氨基酸键联槟榔碱衍生物的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009511450A (ja) * 2005-10-07 2009-03-19 ノバルティス アクチエンゲゼルシャフト ニロチニブとファルネシルトランスフェラーゼ阻害剤の組合せ
JP2014500317A (ja) * 2010-12-20 2014-01-09 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｆｘｒ調節のための組成物および方法
JP2014500318A (ja) * 2010-12-20 2014-01-09 アイアールエム・リミテッド・ライアビリティ・カンパニー ファルネソイドｘ受容体を調節するための組成物および方法
JP2014520823A (ja) * 2011-07-13 2014-08-25 フェネックス ファーマシューティカルス アーゲー 新規なｆｘｒ（ｎｒ１ｈ４）結合および活性調節化合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009511450A (ja) * 2005-10-07 2009-03-19 ノバルティス アクチエンゲゼルシャフト ニロチニブとファルネシルトランスフェラーゼ阻害剤の組合せ
JP2014500317A (ja) * 2010-12-20 2014-01-09 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｆｘｒ調節のための組成物および方法
JP2014500318A (ja) * 2010-12-20 2014-01-09 アイアールエム・リミテッド・ライアビリティ・カンパニー ファルネソイドｘ受容体を調節するための組成物および方法
JP2014520823A (ja) * 2011-07-13 2014-08-25 フェネックス ファーマシューティカルス アーゲー 新規なｆｘｒ（ｎｒ１ｈ４）結合および活性調節化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF LIPID RESEARCH, vol. 48, JPN6019036974, 2007, pages 2693 - 2700, ISSN: 0004121812 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020500211A (ja) * 2016-11-04 2020-01-09 へパジーン セラピューティクス インコーポレイテッド Ｆｘｒモジュレーターとしての窒素含有複素環式化合物
JP7208909B2 (ja) 2016-11-04 2023-01-19 へパジーン セラピューティクス （エイチケイ） リミテッド Ｆｘｒモジュレーターとしての窒素含有複素環式化合物
JP2021501220A (ja) * 2017-11-01 2021-01-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ファルネソイドｘ受容体モジュレーターとしての架橋二環化合物
JP7212693B2 (ja) 2017-11-01 2023-01-25 ブリストル－マイヤーズ スクイブ カンパニー ファルネソイドｘ受容体モジュレーターとしての架橋二環化合物
JP2022518603A (ja) * 2019-01-31 2022-03-15 中国医▲薬▼研究▲開▼▲発▼中心有限公司 芳香環又は芳香族複素環化合物、その製造方法及び医薬使用
JP2023539385A (ja) * 2020-06-30 2023-09-13 オクヴィルク，ゼレン グアニル酸シクラーゼｃ（ｇｕｃｙ２ｃ）アゴニストおよび短鎖脂肪酸またはそのプロドラッグの組み合わせを含む医薬組成物
JP7599014B2 (ja) 2020-06-30 2024-12-12 オクヴィルク，ゼレン グアニル酸シクラーゼｃ（ｇｕｃｙ２ｃ）アゴニストおよび短鎖脂肪酸またはそのプロドラッグの組み合わせを含む医薬組成物
US12599648B2 (en) 2020-06-30 2026-04-14 Sören Ocvirk Pharmaceutical composition comprising a combination of a guanylate cyclase C (GUCY2C) agonist and a short-chain fatty acid or prodrug thereof

Also Published As

Publication number Publication date
PH12017501046A1 (en) 2017-11-27
AU2015365481A1 (en) 2017-06-22
SG11201704340VA (en) 2017-07-28
CL2017001566A1 (es) 2018-03-23
TN2017000243A1 (en) 2018-10-19
IL252596A0 (en) 2017-07-31
RU2017125365A (ru) 2019-01-21
AU2015365481B2 (en) 2018-08-09
WO2016097933A1 (en) 2016-06-23
CA2970866A1 (en) 2016-06-23
KR20170095965A (ko) 2017-08-23
RU2017125365A3 (https=) 2019-07-17
TW201628615A (zh) 2016-08-16
BR112017011972A2 (pt) 2017-12-26
US20190083473A1 (en) 2019-03-21
US20170368038A1 (en) 2017-12-28
EP3233083A1 (en) 2017-10-25
MX2017008057A (es) 2017-09-28
CN107106555A (zh) 2017-08-29

Similar Documents

Publication Publication Date Title
JP2017537960A (ja) 肝疾患および胃腸疾患の治療に使用するためのｆｘｒアゴニストとしてのアザビシクロオクタン誘導体
JP6997870B2 (ja) Ｆｘｒ受容体刺激薬
JP7053478B2 (ja) Ｆｘｒアゴニストを使用するための方法
TWI615393B (zh) 丙烯酸類衍生物、其製備方法及其在醫藥上的用途
JP5740483B2 (ja) Ｆｘｒ調節のための組成物および方法
JP7554739B2 (ja) ファルネソイドｘ受容体アゴニストおよびその使用
TWI537262B (zh) 供治療糖尿病使用之新穎１，２，３，４－四氫喹啉衍生物
RS57179B1 (sr) Kompozicije i postupci za modulaciju farnezoid x receptora
TW201735924A (zh) 使用fxr促效劑之方法
TR201809041T4 (tr) Safra asidinin 11-hidroksil-6-sübstitüe-türevleri ve bunun farnesoid X reseptör modülatörleri olarak amino asit konjugatları.
CN111825701B (zh) 含苯并噻唑的三环类fxr调节剂化合物
RU2827704C1 (ru) Соединения бензотиа(ди)азепина и их применение в качестве модуляторов желчных кислот
TW202311256A (zh) 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑
BR112020000180B1 (pt) Compostos agonistas do receptor fxr, formulação farmacêutica que contém os mesmos e uso dos compostos para prevenir e/ou tratar doenças mediadas por fxr
EA047314B1 (ru) Агонисты фарнезоидного х-рецептора и их применение
HK40016529A (en) Fxr receptor agonist
HK40016529B (en) Fxr receptor agonist

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191001

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200526